Gilead's simtuzumab misses in pancreatic cancer

Gilead Sciences Inc. (NASDAQ:GILD) said simtuzumab ( GS-6624) missed the primary endpoint of progression-free survival (PFS) in a Phase II trial to treat patients with advanced pancreatic cancer.

Patients received intravenous simtuzumab plus Gemzar gemcitabine from Eli Lilly and Co. (NYSE:LLY) or placebo plus Gemzar. Median PFS was 3.5 months for the low-dose simtuzumab group, 3.7 months for the high-dose group and 3.7 months for placebo. ...